retatrutide type 2 diabetes phase 2 trial Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, conducted in the USA Retatrutide Helped Adults With Diabetes

Here are a few of my favorites

Marc Jean-Gilles, DO, FACOG, at Abundant Life Healthcare to determine if GLP-1 medications are right for you

The North America obesity GLP-1 market size is estimated at USD 4.93 billion in 2025 and is projected to reach approximately USD 40.27 billion by 2035, with a 23.37% CAGR from 2026 to 2035

The primary causes include reduced caloric intake, electrolyte imbalances, blood sugar fluctuations, and metabolic adaptation to rapid weight loss

Phentermine and semaglutide and phentermine and tirzepatide are common combinations people ask about

Full-dose GLP-1 therapy focuses on treating obesity and metabolic disease